Harvard Bioscience (HBIO) Non-Current Debt (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Non-Current Debt data on file, last reported at $36.2 million in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $36.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $36.2 million (changed N/A YoY), and the FY2025 annual result was $35.9 million, changed N/A from the prior year.
• Non-Current Debt rose to $36.2 million in Q1 2026 per HBIO's latest filing, from $35.9 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $46.5 million in Q3 2022 and troughed at $30.7 million in Q4 2023.
• A 5-year average of $38.2 million and a median of $36.2 million in 2026 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2022 and 2023: Non-Current Debt increased 11.83% in 2022, then declined 28.62% in 2023.
• A 5-year view of Non-Current Debt shows it stood at $43.0 million in 2022, then decreased by 28.62% to $30.7 million in 2023, then grew by 11.56% to $34.3 million in 2024, then rose by 4.72% to $35.9 million in 2025, then rose by 0.95% to $36.2 million in 2026.
• Business Quant data shows HBIO's Non-Current Debt at $36.2 million in Q1 2026, $35.9 million in Q4 2025, and $34.3 million in Q3 2024.